Abstract
In the era of combinatorial chemistry and high-throughput screening, a huge number of hits and structural analogs potentially interesting as new chemical entities (NCEs) can be produced in a short period of time. Drug metabolism is a decisive determinant of the pharmacokinetic behavior of these compounds. Approximately three quarters of the top 200 prescribed drugs in the United States in 2002 are cleared by metabolism, one-third are cleared via the kidney, while biliary clearance of unchanged drug plays only a minor role (Williams et al. 2004). Thus, understanding and description of the metabolism of a new chemical entity is an essential part of the submission dossier (Weaver and Jochemsen 2009) as well as an important optimization parameter in drug discovery programs to reduce attrition in drug development (Kola and Landis 2004)
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Selection of an adequate batch of collagenase is the key critical step for successful isolation of human hepatocytes. Whereas the majority of all collagenases allow successful isolation of rat hepatocytes, selection of a good batch for human liver is more critical. Mostly, the collagenase concentration has to be optimized for an individual batch of collagenase.
References and Further Reading
Aragon CMG, Rogan F, Amit Z (1992) Ethanol metabolism in rat brain homogenate by catalase-H2O2 system. Biochem Pharmacol 44:93–98
Arinc E (2010) The role of polymorphic cytochrome P450 enzymes in drug design, development and drug interactions with a special emphasis on phenotyping. J Mol Catal B Enzym 64:120–122
Baciewicz FA Jr, Arredondo M, Chaudhuri B, Crist KA, Basilius D, Bandyopadhyah S, Thomford NR, Chaudhuri PK (1991) Pharmacokinetics and toxicity of isolated perfusion of lung with doxorubicin. J Surg Res 50:124–128
Bader A, Fruehauf N, Zech K, Haverich A, Borlak JT (1998) Development of a small-scale bioreactor for drug metabolism studies maintaining hepatospecific functions. Xenobiotica 9:815–825
Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossmann SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188–196
Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossmann SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA (2003) Reply to the editor (see also Hastings et al. 2003). Toxicol Appl Pharmacol 190:93–94
Balbach S, Korn C (2004) Pharmaceutical evaluation of early development candidates: “the 100 mg-approach”. Int J Pharm 275:1–12
Balimane P, Sinko P (2000) Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells. Biopharm Drug Dispos 21:165–174
Baranczewski P, Stanczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P, Postlind H (2006) Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 58:453–472
Beaune P, Kremers PG, Kaminsky LS, De Graeve J, Albert A, Guengerich FP (1986) Comparison of monooxygenase activities and cytochrome P-450 isozyme concentration in human liver microsomes. Drug Metab Dispos 14:437–442
Benedetti MS, Whomsley R, Baltes E (2006) Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics. Expert Opin Drug Metab Toxicol 2:895–921
Bernardelli P, Gaudillière B, Vergne F (2002) Trends and perspectives. In: Doherty AM (ed) To market, to market – 2001, vol 37, Annual reports in medicinal chemistry. Academic, San Diego, pp 257–277 (Chap 26)
Birkett DJ, Mackenzie PI, Veronese ME, Miners JO (1993) In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 14:292–294
Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. Drug Metab Dispos 31:815–832
Blanchard N, Alexandre E, Abadie C, Lave T, Heyd B, Mantion G, Jaeck D, Richert L, Coassoli P (2005) Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes. Xenobiotica 35(1):1–15
Blanchard N, Richert L, Notter B, Delobel F, David P, Coassolo P, Lave T (2004) Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. Eur J Pharm Sci 23:189–199
Bloomer JC, Boyd HF, Hickey DMB, Ife RJ, Leach CA, Macphee CH, Milliner KJ, Pinto IL, Rawlings DA, Smith SA, Stansfield JG, Stanway SJ, Taylor MA, Theobald CJ, Whittaker CM (2001) 1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A2. Bioorg Med Chem Lett 11:1925–1929
Boernsen KO, Floeckher JM, Bruin GJM (2000) Use of a microplate scintillation counter as a radioactivity detector for miniaturized separation techniques in drug metabolism. Anal Chem 72:3956–3959
Boyer-Joubert C, Lorthiois E, Moreau F (2003) Trends and perspectives. In: Doherty AM (ed) To market, to market – 2002, vol 38, Annual reports in medicinal chemistry. Academic, San Diego, pp 347–374 (Chap 33)
Brandon EFA, Raap CD, Meijerman I, Beijnen JH, Schellens JHM (2003) An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 189:233–246
Browne TR, Szabo GK, Ajami A, Wagner D (1993) Performance of human mass balance/metabolite identification studies using stable isotope (13C, 15N) labeling and continuous-flow isotope-ratio mass spectrometry as an alternative to radioactive labeling methods. J Clin Pharmacol 33:246–252
Bu HZ, Pool WF, Wu EY, Raber SR, Amantea MA, Shetty BV (2004) Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos 32:689–698
Bugrim A, Nikolkaya T, Nikolsky Y (2004) Early prediction of drug metabolism and toxicity: systems biology approach and modelling. Drug Discov Today 9:127–135
Busby WF, Ackermann JM, Crespi CL (1999) Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246–249
Chen G, Zhang D, Jing N, Yin S, Falany CN, Radominska-Pandya A (2003) Human intestinal sulfotransferases: identification and distribution. Toxicol Appl Pharmacol 187:186–197
Chen GP, Battaglia E, Senay C, Falany CN, Radominska-Pandya A (1999) Photoaffinity labelling probe for the substrate binding site of human phenol sulfotransferase (SULT1A1): 7-azido-methylcoumarin. Protein Sci 8:2151–2157
Chien DS, Tang-Lieu DDS (1990) Enzymatic hydrolysis of 1-isopropyl prostaglandin F2-alpha in human plasma and liver homogenate. Pharm Res 7(Suppl):S216
Chohan KK, Paine SW, Waters NJ (2006) Quantitative structure activity relationships in drug metabolism. Curr Top Med Chem 6:1569–1578
Clarke NJ, Rindgen D, Korfmacher WA, Cox KA (2001) Systematic LC/MS metabolite identification in drug discovery. Anal Chem 73:430A–439A
Clement B, Lopian K (2003) Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Dispos 31:645–651
Clohs L, Wong J (2002) Validation of a capillary electrophoresis assay for assessing the metabolic stability of verapamil in human liver microsomes. J Capill Electrophor Microchip Technol 7:113
Coleman RA, Bowen WP, Baines IA, Woodrooffe AJ, Brown AM (2001) Use of human tissue in ADME and safety profiling of development candidates. Drug Discov Today 6:1116–1126
Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T, Nuessler A, Neuhaus P, Zanger UM, Eichelbaum M, Muerdter TE (2002) The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antiestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 54:157–167
Combes RD, Berridge T, Connelly J, Eve MD, Garner RC, Toon S, Wilcox P (2003) Early microdose drug studies in human volunteers can minimise animal testing: proceedings of a workshop organised by volunteers in research and testing. Eur J Pharm Sci 19:1–11
Cong D, Fong AK, Lee R, Pang KS (2001) Absorption of benzoic acid in segmental regions of the vascularly perfused rat small intestine preparation. Drug Metab Dispos 29:1539–1547
Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu NW (2003) Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos 31:1448–1455
Coughtrie MWH, Fisher MB (2003) The role of sulfotransferase and UDP-glucuronosyltransferases. In: Lee JS, Obach RS, Fisher MB (eds) Drug metabolizing enzymes. Marcel Dekker, New York, pp 541–575
Cross DM, Bayliss MK (2000) A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development. Drug Metabol Rev 32:219–240
Csala M, Staines AG, Banhegyi G, Mandl J, Coughtrie MW, Burchell B (2004) Evidence for multiple glucuronide transporters in rat liver microsomes. Biochem Pharmacol 68:1353–1362
Cui D, Subramanian R, Shou M, Yu X, Wallace MA, Braun MP, Arison BH, Yergey JA, Prueksaritanont T (2004) In vitro and in vivo metabolism of a potent and selective integrin αvβ3 antagonist in rats, dogs, and monkeys. Drug Metab Dispos 32:848–861
Davis-Bruno KL, Atrakchi A (2006) A regulatory perspective on issues and approaches in characterizing human metabolites. Chem Res Toxicol 19:1561–1563
De Graaf IAM, Van Meijern CE, Pektas F, Koster HJ (2002) Comparison of in vitro preparations for semi-quantitative prediction of in vivo drug metabolism. Drug Metab Dispos 30:1129–1136
De Kanter R, Koster HJ (1995) Cryopreservation of rat and monkey liver slices. Altern Lab Anim 23:653–665
De Kanter R, Olinga P, De Jager MH, Merema MT, Meijer DKF, Groothius GMM (1999) Organ slices as an in vitro test system for drug metabolism in human liver, lung and kidney. Toxicol In Vitro 13:737–744
Dear GJ, Plumb RS, Sweatman BC, Parry PS, Roberts AD, Lindon JC, Nicholson JK, Ismail IM (2000a) Use of directly coupled ion-exchange liquid chromatography-mass spectrometry and liquid chromatography-nuclear magnetic resonance spectroscopy as a strategy for polar metabolite identification. J Chromatogr B Biomed Sci Appl 748:295–309
Dear GJ, Plumb RS, Sweatman BC, Ayrton J, Lindon JC, Nicholson JK, Ismail IM (2000b) Mass directed peak selection, an efficient method of drug metabolite identification using directly coupled liquid chromatography-mass spectrometry-nuclear magnetic resonance spectroscopy. J Chromatogr B Biomed Sci Appl 748:281–293
Di D, Kerns EH, Hong Y, Kleintop TA, McConnell OJ, Huryn DM (2003) Optimization of a Higher Throughput Microsomal Stability Screening Assay for Profiling Drug Discovery Candidates. J Biomolecular Screening 8:453–462
Diana GD, Rudewicz P, Pevear DC, Nitz T, Aldous SC, Aldous DJ, Robinson DT, Draper T, Dutko FJ, Aldi C, Gendron G, Oglesby RC, Volkots DB, Reuman M, Bailey TR, Czerniak R, Block T, Roland R, Oppermann J (1995) Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. J Med Chem 38:1355–1371
Di-Stefano A, Mosciatti B, Cingolani GM, Giorgioni G, Ricciutelli M, Cacciatore I (2001) Dimeric L-dopa derivatives as potential prodrugs. Bioorg Med Chem Lett 11:1085–1088
Dogterom P (1993) Development of a simple incubation system for metabolism studies with precision-cut liver slices. Drug Metab Dispos 21:699–704
Donato MT, Castell JV (2003) Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism – focus on in vitro studies. Clin Pharmacokinet 42:153–178
Dutheil F, Dauchy S, Diry M, Sazdovitch V, Cloarec O, Mellottée L, Bièche I, Ingelman-Sundberg M, Flinois JP, de Waziers I, Beaune P, Declèves X, Duyckaerts C, Loriot M-A (2009) Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos 37:1528–1538
Easterbrook J, Lu C, Sakai Y, Li AL (2001) Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 29:141–144
Eddershaw PJ, Beresford AP, Bayliss MK (2000) ADME/PK as part of a rational approach to drug discovery. Drug Discov Today 5:409–414
Ekins S, Mäenpää J, Wrighton S (1999) In vitro metabolism: subcellular fractions. In: Wolf TF (ed) Handbook of drug metabolism. Marcel Dekker, New York, pp 363–399
EMA (European Medicines Agency) Guidance (2012) Guideline on the investigation of drug interactions. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf. Accessed in July 2012
Enser MB, Kunz F, Borensztajn J, Opie LH, Robinson DS (1967) Metabolism of triglyceride fatty acid by the perfused rat heart. Biochem J 104:306–317
Epperly AH, Cai Z, Depée SP, Harrelson SL, Sinhababu AK, Tyler LO, Wells-Knecht MC, Davis-Ward RG, Harris P, Mook RA, Luttrell DK, Stafford JA (2001) Pharmacokinetic analysis of a series of dianilinopyrimidine inhibitors of VEGFR2 tyrosine kinase: correlation of the in vitro and in vivo metabolic stability of a specific glucuronidation reaction and the discovery of GW2286. Drug Metab Rev 33:243
Ethell BT, Anderson GD, Beaumont K, Rance DJ, Burchell B (1998) A universal radiochemical HPLC assay for the determination of UDP-glucuronosyltransferase activity. Biochemistry 255:142–147
Ethell BT, Riedel J, Englert H, Jantz H, Oekonomopulos R, Burchell B (2003) Glucuronidation of HMR1098 in human microsomes: evidence for the involvement of UGT1A1 in the formation of S-glucuronides. Drug Metab Dispos 31:1027–1034
Favetta P, Guitton J, Degoute CS, Van Deale L, Boulieu R (2000) High-performance liquid chromatographic assay to detect hydroxylated and conjugated metabolites of propofol in human urine. J Chromatogr B 742:25–35
Fisher MB, Campanale K, Ackermann BL, Vandenbranden M, Wrighton S (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560–566
Fisher RL, Shaughnessy RP, Jenkins PM, Austin ML, Roth GL, Gandolfi AJ, Brendel K (1995) Dynamic organ culture is superior to multiwell plate culture for maintaining precision-cut tissue slices. 1. Optimization of the tissue slice culture. Toxicol Methods 5:99–113
Forster RP (1948) Use of thin kidney slices and isolated renal tubules for direct study of cellular transport kinetics. Science 108:65–67
Frandsen H, Alexander J (2000) N-Acetyltransferase-dependent activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine: formation of 2-amino-1-methyl-6-(5-hydroxy)phenylimidazo[4,5-b]pyridine, a possible biomarker for the reactive dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Carcinogenesis 21:1197–1203
Friedberg T, Henderson CJ, Pritschard MP, Wolf CR (1999) In vivo and in vitro recombinant DNA technology as a powerful tool in drug development. In: Wolf TF (ed) Handbook of drug metabolism. Marcel Dekker, New York, pp 321–362
Galetin A, Gertz M, Houston JB (2008) Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 4:909–922
Gao H, Deng S, Obach RS (2010) A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments. Drug Metab Dispos 38:2147–2156
Garattini E, Fratelli M, Terao M (2008) Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell Mol Life Sci 65:1019–1048
Garner RC (2000) Accelerator mass spectrometry in pharmaceutical research and development – a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 1:205–213
Garner RC, Barker J, Flavell C, Garner JV, Whattam M, Young GC, Cussans N, Jezequel S, Leong D (2000) A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J Pharm Biomed Anal 24:197–209
Gebhardt R, Hengstler JG, Mueller D, Gloeckner R, Buenning P, Laube B, Schmelzer E, Ullrich M, Utesch D, Hewitt N, Ringel M, Reeder Hilz B, Bader A, Langsch A, Koose T, Burger HJ, Maas J, Oesch F (2003) New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendation for application in basic research and drug development, standard operation procedures. Drug Metab Rev 35:145–213
Gergel D, Misik V, Ondrias K (1992) Effect of cisplatin, carboplatin and stobadine on lipid peroxidation of kidney homogenate and phosphatidylcholine liposomes. Physiol Res 41:129–134
Gombar VK, Silver IS, Zhao Z (2003) Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability. Curr Top Med Chem 3:1205–1225
Gómez-Lechón MJ, Castell JV, Donato MT (2008) An update on metabolism studies using human hepatocytes in primary culture. Expert Opin Drug Metab Toxicol 4:837–854
Gonzalez FJ, Kimura S (2003) Study of P450 function using gene knockout and transgenic mice. Arch Biochem Biophys 409:153–158
Griffin SJ, Houston JB (2005) Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspensions and monolayer cultures. Drug Metab Dispos 33:115–120
Guengerich FP (2006) Safety assessment of stable drug metabolites. Chem Res Toxicol 19:1559–1560
Guillouzo A (1995) Acquisition and use of human in vitro liver preparations. Cell Biol Toxicol 11:141–145
Gupta RC, Atul BV (2000) Drug metabolism studies in animal models. Indian J Pharmacol 32:S62–S66
Guyomard C, Rialland L, Fremond B, Chesne C, Guillouzo A (1996) Influence of alginate gel entrapment and cryopreservation on survival and xenobiotic metabolism capacity of rat hepatocytes. Toxicol Appl Pharmacol 141:349–356
Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ (1997) Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Arch Biochem Biophys 337:275–283
Hastings KL, El-Hage J, Jacobs A, Leighton J, Morse D, Osterberg RE (2003) Letter to the editor (see also Baillie et al. 2003). Toxicol Appl Pharmacol 190:91–92
Hayakawa H, Fukushima Y, Kato H, Fukumoto H, Kadota T, Yamamoto H, Kuroiwa H, Nishigaki J, Tsuji A (2003) Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters. Drug Metab Dispos 31:1409–1418
Hengstler JG, Arand M, Herrero ME, Oesch F (1998) Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res 154:47–85
Hengstler JG, Ringel M, Biefang K, Hammel S, Milbert U, Gerl M, Klebach M, Diener B, Platt KL, Böttger T, Steinberg P, Oesch F (2000a) Cultures with cryopreserved hepatocytes: applicability for studies of enzyme induction. Chem Biol Interact 125:51–73
Hengstler JG, Utesch D, Steinberg P, Platt KL, Diener B, Swales N, Fischer T, Biefang K, Gerl M, Böttger T, Oesch F (2000b) Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab Rev 32:81–118
Hewawasam P, Erway M, Moon SL, Knipe J, Weiner H, Boissard CG, Post-Munson DJ, Gao Q, Huang S, Gribkoff VK, Meanwell NA (2002) Synthesis and structure-activity relationships of 3-aryloxindoles: a new class of calcium-dependent, large conductance potassium (maxi-K) channel openers with neuroprotective properties. J Med Chem 45:1487–1499
Hewitt NJ, Lechón MJG, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, Lecluyse E, Groothuis GMM, Hengstler JG (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159–234
Holland JF, Leary JJ, Sweeley CC (1986) Advanced instrumentation and strategies for metabolic profiling. J Chromatogr 379:3–26
Hornykiewicz O (2002) Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 17:501–508
Houston JB (1994a) Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics. Toxicol In Vitro 8:507
Houston JB (1994b) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469
Humphreys WG, Unger SE (2006) Safety assessment of drug metabolites: characterization of chemically stable metabolites. Chem Res Toxicol 19:1564–1569
Huryn DM, Ashwell S, Baudy R, Dressen DB, Gallaway W, Grant FS, Konradi A, Ley RW, Petusky S, Pleiss MA, Sarantakis D, Semko CM, Sherman MM, Tio C, Zhang L (2004) Synthesis, characterization and evaluation of pro-drugs of VLA-4 antagonists. Bioorg Med Chem Lett 14:1651–1654
Huskey SEW, Dean BJ, Doss GA, Wang Z, Hop CECA, Anari R, Finke PE, Robichaud AJ, Zhang M, Wang B, Strauss JR, Cunningham PK, Feeney WP, Franklin RB, Naillie TA, Chiu SHL (2004) The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. Drug Metab Dispos 32:246–258
ICH Topic M3 (R2) (2009) Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf. Accessed in Dec 2011
Igarashi T, Satoh T (1989) Sex and species differences in glutathione S-transferase activities. Drug Metabol Drug Interact 7:191–212
Iley J, Mendes E, Moreira R, Souza S (1999) Cleavage of tertiary amidomethyl ester prodrugs of carboxylic acids by rat liver homogenate. Eur J Pharm Sci 9:201–205
Inaba T, Kovacs J (1989) Haloperidol reductase in human and guinea pig livers. Drug Metab Dispos 17:330–333
Inskeep PB, Day WW (1999) Preclinical drug metabolism studies and strategies. In: Wolf TF (ed) Handbook of drug metabolism. Marcel Dekker, New York, pp 551–576
Iwatsubo T, Hirota N, Ooie T, Suzuki H, Sugiyama Y (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17:273
Iyer RA, Malhotra B, Khan S, Mitroka J, Bonacorsi S, Waller SC, Rinehart JK, Kripalani K (2003) Comparative biotransformation of radiolabelled [14C]omapatrilat and stable-labeled [13C2]omapatrilat after oral administration to rats, dogs and humans. Drug Metab Dispos 31:67–75
Iyer RA, Mitroka J, Malhotra B, Bonacorsi S, Waller SC, Rinehart JK, Roongta VA, Kripalani K (2001) Metabolism of [14C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans. Drug Metab Dispos 29:60–69
Jones H, Houston JB (2004) Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 32:973–982
Jones BC, Hyland R, Ackland M, Tyman C, Smith DD (1998) Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6. Drug Metab Dispos 26:875–882
Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O'Donnell JP, Boer J, Harriman SP (2005) A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 6:161–225
Kaminsky LS, Zhang QY (2003) The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos 31:1520–1525
Kaneda Y, Liu D, Brooks A, Abolhoda A, Labow D, Burt ME, Ginsberg RJ (2001) Toxicity and pharmacokinetics of isolated lung perfusion with cisplatin in rat. Jpn J Thorac Cardiovasc Surg 49:443–448
Kern A, Bader A, Pichlmayr R, Sewing K-F (1997) Drug metabolism in hepatocytes sandwich cultures of rats and humans. Biochem Pharmacol 54:761–772
Kiffe M, Jehle A, Ruembeli R (2003) Combination of high-performance liquid chromatography and microplate scintillation counting for crop and animal metabolism studies: a comparison with classical on-line and thin-layer chromatography radioactivity detection. Anal Chem 75:723–730
Klieber S, Torreilles F, Guillou F, Fabre G (2010) The use of human hepatocytes to investigate drug metabolism and CYP enzyme induction. Methods Mol Biol 640:295–308
Kling A, Backfisch G, Delzer J, Geneste H, Graef C, Hornberger W, Lange UEW, Lauterbach A, Seitz W, Subkowski T (2003) Design and synthesis of 1,5- and 2,5-substituted tetrahydrobenzazepinones as novel potent and selective integrin αvβ3 antagonists. Bioorg Med Chem 11:1319–1341
Knudsen CA, Tappel AL, North JA (1996) Multiple antioxidants protect against heme protein and lipid oxidation in kidney tissue. Free Radic Biol Med 20:165–173
Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates. Nat Rev Drug Discov 3:711–715
Koop DR (1992) Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 6:724–730
Krone V, Kuerzel GU, Shackleton G, Zimmer M (2011) The human ADME study. In: Vogel HG (ed) Drug discovery and evaluation: methods in clinical pharmacology. Springer, Heidelberg, pp 73–104
Krumdieck CL, Dos Santos JE, Ho K-J (1980) A new instrument for the rapid preparation of tissue slices. Anal Biochem 104:118–123
Kuehl G, Murphy S (2003) N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases. Drug Metab Dispos 31:1361–1368
Kumar GN, Surapaneni S (2001) Role of drug metabolism in drug discovery and development. Med Res Rev 21:397–411
Lafleur MA, Hollenberg MD, Atkinson SJ, Knauper V, Murphy G, Edwards DR (2001) Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. Biochem J 357:107–115
Lan SJ, Scanlan LM, Weinstein SH, Varma RK, Warrack BM, Unger SE, Porubcan MA, Migdalof BH (1989) Biotransformation of tipredane, a novel topical steroid, in mouse, rat and human liver homogenates. Drug Metab Dispos 17:532–541
Lang D, Kalgutkar AS (2003) Non-P450 mediated oxidative metabolism of xenobiotics. In: Lee JS, Obach RS, Fisher MB (eds) Drug Metabolizing Enzymes. Marcel Dekker, New York, pp 483–539
Lantz RJ, Gillespie TA, Rash TJ, Kuo F, Skinner M, Kuan HY, Knadler MP (2003) Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 31:1142–1150
Lappin G, Stevens L (2008) Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin Drug Metab Toxicol 4:1021–1033
Lee JS, Obach RS, Fisher MB (eds) (2003) Drug metabolizing enzymes, cytochrome P450 and other enzymes in drug discovery and development. Marcel Dekker, New York
Lee ML, Stavchansky S (1995) Enhancement of thymopentin stability in human plasma. Pharm Res 12:S323
Lee PC, Marquardt M, Lech JJ (1998) Metabolism of nonylphenol by rat and human microsomes. Toxicol Lett 99:117–126
Lee SH, Slattery JT (1997) Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Drug Metab Dispos 25:1354–1358
Lewis AJ, Otake Y, Walle UK, Walle T (2000) Sulphonation of N-hydroxy-2-acetylaminofluorene by human dehydroepiandrosterone sulphotransferase. Xenobiotica 30:253–261
Li AP (1999) Cryopreserved human hepatocytes: characterization of DME activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 121:17–35
Li AP (2002) Early ADME/Tox studies and in silico screening. Drug Discov Today 7:25–27
Li AP (2004) In vitro approaches to evaluate ADMET drug properties. Curr Top Med Chem 4:701–706
Li AP (2007) Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem Biol Int 168:16–29
Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, Mendel DB (1998) Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 42:647–653
Linget JM, du Vignaud P (1999) Automation of metabolic stability studies in microsomes, cytosol and plasma using a 215 Gilson liquid handler. J Pharm Biomed Anal 19:893–901
Lipscomp JC, Poet TS (2008) In vitro measurements of metabolism for application in pharmacokinetic modeling. Pharmacol Ther 118:82–103
Long L, Dolan RC, Dolan ME (2001) Debenzylation of O6-benzyl-8-oxoguanine in human liver: implications for O6-benzylguanine metabolism. Biochem Pharmacol 61:721–726
Los LE, Welsh DA, Herold EG, Bagdon WJ, Zacchei A (1996) Gender differences in toxicokinetics, liver metabolism, and plasma esterase activity: observations from a chronic (27-week) toxicity study of enalapril/diltiazem combinations in rats. Drug Metab Dispos 24:28–33
Lu AYH, Wang RW, Lin JH (2003) Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 31:345–350
Luffer-Atlas D (2008) Unique/major human metabolites: why, how, and when to test for safety in animals. Drug Metab Rev 40:447–463
MacKenzie AR, Marchington AP, Middleton DS, Newman SD, Jones BC (2002) Structure-activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)-5-(2-((3-substituted)-1-azetidinyl)-ethyl)-2-piperidones. 1. Selective antagonists of the neurokinin-2 receptor. J Med Chem 45:5365–5377
Mae T, Inaba T, Konishi E, Hosoe K, Hidaka T (2000) Identification of enzymes responsible for rifalazil metabolism in human liver microsomes. Xenobiotica 30:565–574
Mahfouz NM, Omar FA, Aboul-Fadl T (1999) Cyclic amide derivatives as potential prodrugs II: N-hydroxymethylsuccinimide-/isatin esters of some NSAIDs as prodrugs with an improved therapeutic index. Eur J Med Chem 34:551–562
Manautou JE, Buss NJ, Carlson GP (1992) Oxidative and non-oxidative metabolism of ethanol by the rabbit lung. Toxicol Lett 62:93–99
Mandagere AK, Thompson TN, Hwang KK (2002) Graphical model for estimating the oral bioavailability of drugs in humans and other species from their CaCo-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 45:304–311
Mandan A, Usuki E, Burton LA, Ogilvie BW, Parkinson A (2002) In vitro approaches for Studying the inhibition of drug-metabolizing enzymes and the identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In: Rodrigues AD (ed) Drug-drug interactions. Marcel Dekker, Inc. pp 217–294
Maron DM, Ames BN (1983) Revised methods for the Salmonella mutagenicity test. Mutat Res 113:173–215
Martignoni M, Groothuis GMM, de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–894
Masimirembwa CM, Bredberg U, Andersson TB (2003) Metabolic stability for drug discovery and development. Pharmacokinetic and biochemical challenges. Clin Pharmacokinet 42:515–528
Maslansky CJ, Williams GM (1982) Primary cultures and the levels of cytochrome P450 in hepatocytes from mouse, rat, hamster and rabbit liver. In Vitro 18:683–693
Maurel P (1996) The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man. Adv Drug Deliv Rev 22:105–132
McGinnity DF, Parker AJ, Soars M, Riley RJ (2000) Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab Dispos 28:1327–1334
Meier PJ, Mueller HK, Dick B, Meyer UA (1983) Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 85:682–692
Mitsuya M, Kobayashi K, Kawakami K, Satoh A, Ogino Y, Kakikawa T, Ohtake N, Kimura T, Hirose H, Sato A, Numazawa T, Hasegawa T, Noguchi K, Mase T (2000) A Potent, Long-Acting, Orally Active (2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: A Novel Muscarinic M3 Receptor Antagonist with High Selectivity for M3 over M2 Receptors. J Med Chem 43:5017–5029
Murray M (1984) Mechanisms of the inhibition of cytochrome P-450- mediated drug oxidation by therapeutic agents. Drug Metab Rev 18:55–8149
Nassar AEF, Talaat RE (2004a) Strategies for dealing with metabolite elucidation in drug discovery and development. Drug Discov Today 9:317–327
Nassar AE, Parmentier Y, Martinet M, Lee DY (2004b) Liquid chromatography-accurate radioisotope counting and microplate scintillation counter technologies in drug metabolism studies. J Chromatogr Sci 42:348–353
Nedderman ANR, Dear GJ, North S, Obach RS, Higton D (2011) From definition to implementation: a cross-industry perspective of past, current and future MIST strategies. Xenobiotica 41:605–622
Newton DJ, Wang RW, Lu AYH (1995) Cytochrome P450 inhibitors – evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154–158
Newton JF Jr, Hook JB (1981) Isolated perfused rat kidney. Methods Enzymol 77:94–105
Nizet A (1975) The isolated perfused kidney: possibilities, limitations and results. Kidney Int 7:1–11
Norton RM, White HL, Cooper BR (1992) Metabolism of BW1370U87 by crude liver homogenate from several species: an in vitro method for preliminary investigation of species differences in metabolism. Drug Dev Res 25:229–234
Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58
Obach RS, Huynh P, Allen MC (2004) Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:7–19
Obach RS, Nedderman AN, Smith DA (2012) Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary? Xenobiotica 42:46–56
Obach RS, Reed-Hagem AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831–837
Oesch F, Fabian E, Oesch-Bartlomowicz B, Werner C, Landsiedel R (2007) Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab Rev 39:659–698
Ohno S, Nakajin S (2009) Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32–40
Ohta N, Yotsuyanagi T, Ikeda K (1987) Esterase-like activity of human serum albumin toward 4′-methylumbelliferyl 4-guanidinobenzoate. J Pharm Sci 76:S285
Olinga P, Merema M, Hof IH, De Jong KP, Sloof MJH, Meijer DKF, Groothuis GMM (1998) Effect of human liver source on the functionality of isolated hepatocytes and liver slices. Drug Metab Dispos 26:5–11
Omiecinski CJ, Hassett C, Hosagrahara V (2000) Epoxide hydrolase-polymorphism and role in toxicology. Toxicol Lett 112–113:365–370
Otsuka M, Mine T, Ohuchi K, Ohmori S (1996) A detoxification route for aldehyde: metabolism of diacetyl, acetoin and 2,3-butanediol in liver homogenate and perfused liver of rats. J Biochem 119:246–251
Paine MF, Thummel KE (2003) Role of intestinal cytochrome P450 in drug disposition. In: Lee JS, Obach RS, Fisher MB (eds) Drug metabolizing enzymes, cytochrome P450 and other enzymes in drug discovery and development. Marcel Dekker, New York, pp 421–453
Pang KS, Cherry WF, Ulm EH (1985) Disposition of enalapril in the perfused rat intestine-liver preparation: absorption, metabolism and first-pass effect. J Pharmacol Exp Ther 233:788–795
Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C, Parkinson A (1996) Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 331:145–169
Pichard L, Raulet E, Fabre G, Ferrini JB, Ourlin JC, Maurel P (2006) Human hepatocyte culture. Methods Mol Biol 320:283–293
Plant N (2004) Strategies for using in vitro screens in drug metabolism. Drug Discov Today 9:328–336
Plobeck N, Delorme D, Wie Z-Y, Yang H, Zhou F, Schwarz P, Gawell L, Gagnon H, Pelcman B, Schmidt R, Yue SY, Walpole C, Brown W, Zhou E, Labarre M, Payza K, St-Onge S, Kamassah A, Morin P-E, Projean D, Ducharme J, Roberts E (2000) New Diarylmethylpiperazines as Potent and Selective Nonpeptidic ‰ Opioid Receptor Agonists with Increased In Vitro Metabolic Stability. J Med Chem 43:3878–3894
Pool WF (1999) Clinical drug metabolism studies. In: Wolf TF (ed) Handbook of drug metabolism. Marcel Dekker, New York, pp 577–587
Poon GK, Walter B, Lonning PE, Horton MN, McCague R (1995) Identification of Tamoxifen metabolites in human HEP G2 cell line, liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab Dispos 23:377–382
Potter VR, Elvehjem CA (1936) A modified method for the study of tissue oxidation. J Biol Chem 114:495–504
Powell MF, Stewart T, Otvos L Jr, Urge L, Gaeta FC, Sette A, Arrhenius T, Thomson D, Soda K, Colon SM (1993) Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm Res 10:1268–1273
Prakash C, Sharma R, Gleave M, Nedderman A (2008) In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery. Curr Drug Metab 9:952–964
Price-Evans DA (1989) N-acetyltransferase. Pharmacol Ther 42:157–234
Quon CY, Stampfli H (1985) Biochemical properties of blood esmolol esterase. Drug Metab Dispos 13:420–424
Quon CY, Stampfli HF (1993) Biochemical characterization of flestolol esterase. Res Commun Chem Pathol Pharmacol 81:309–322
Rajanikanth M, Madhusudanan KP, Gupta RC (2003) Simultaneous quantitative analysis of three drugs by high-performance liquid chromatography/electrospray ionization mass spectrometry and its application to cassette in vitro metabolic stability studies. Rapid Commun Mass Spectrom 17:2063–2070
Raney KD, Meyer DJ, Ketterer B, Harris TM, Guengerich FP (1992) Glutathione conjugation of aflatoxin B1 exo- and endo-epoxides by rat and human glutathione S-transferases. Chem Res Toxicol 5:470–478
Raucy JI, Laskor JM (1991) Isolation of P450 enzyme from human liver. Methods Enzymol 206:577–587
Rettie AE, Meier GP, Sadeque AJM (1995) Prochiral sulfides as in vitro probes for multiple forms of the flavin-containing monooxygenase. Chem Biol Interact 96:3
Rialland L, Guyomard C, Scotte M, Chesne C, Guillouzo A (2000) Viability and drug metabolism capacity of alginate-entrapped hepatocytes after cryopreservation. Cell Biol Toxicol 16:105–116
Ritter JK (2000) Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 129:171–193
Ritter JK (2006) Intestinal UGT’s as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin Drug Metab Toxicol 3:93–107
Rodrigues AD (1999) Applications of heterologous expressed and purified human drug-metabolizing enzymes: an industrial perspective. In: Wolf TF (ed) Handbook of drug metabolism. Marcel Dekker, New York, pp 279–320
Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, Gottesdiener KM, Larson PJ, Lasseter KC, Agrawal NGB (2003) Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos 31:224–232
Roediger WEW, Babidge W (1997) Human colonocyte detoxification. Gut 41:731–734
Ruegg CE, Gandolfi AJ, Nagle RB, Krumdieck CL, Brendel K (1987) Preparation of positional renal slices for study cell specific toxicity. J Pharmacol Methods 17:111–123
Sandvoss M, Roberts AD, Ismail IM, North SE (2004) Direct on-line hyphenation of capillary liquid chromatography to nuclear magnetic resonance spectroscopy: practical aspects and application to drug metabolite identification. J Chromatogr A 1028:259–266
Scheuer J, Olson RE (1967) Metabolism of exogenous triglyceride by the isolated perfused rat heart. Am J Physiol 212:301–307
Scriba GKE (1993) In-vitro evaluation of 4-(2-glyceryl)-butyric acid for lipase-driven drug delivery. Pharm Res 10:S295
Seglen PO (1976) Preparation of isolated rat liver cells. Methods Cell Biol 13:29–83
Shearer T, Rettberg B, Milhous W, Weina P, Hanahan J, Quartucci S (2002) In vitro metabolism of anticolates candidate antimalaria drugs. Am J Trop Med Hyg 67:306
Shin H-C, Kim H-R, Cho H-J, Yi H, Cho S-M, Lee D-G, El-Aty AMA, Kim J-S, Sun D, Amidon GL (2009) Comparative gene expression of intestinal metabolizing enzymes. Biopharm Drug Dispos 30:411–421
Shipkova M, Armstrong VW, Oellerich M, Wieland E (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25:1–16
Sidelmann UG, Comett C, Tjornelund J, Hansen SH (1996) A comparative study of precision cut liver slices, hepatocytes and liver microsomes from the Wistar rat using metronidazole as a model substance. Xenobiotica 26:709–722
Sindhu RK, Kikkawa Y (1995) Metabolism of (+)-trans-benzo[a]pyrene-7,8-dihydrodiol by 3-methylcholanthrene-induced liver homogenate. Toxicol Lett 82:5–13
Slone DH, Gallagher EP, Ramsdell HS, Rettie AE, Stapleton PL, Berlad LG, Eaton DL (1995) Human variability in hepatic glutathione S-transferase-mediated conjugation of aflatoxin B1-epoxide and other substrates. Pharmacogenetics 5:224–233
Smith DA (2011) The debate is over: accelerator MS provides the route to better drug-development paradigms/protocols. Bioanalysis 3:391–392
Smith DA, Obach RC (2006) Metabolites and safety: what are the concerns, and how should we address them? Chem Res Toxicol 19:1570–1579
Smith PF, Gandolfi AJ, Krumdieck CL, Putnam CW, Zukosi CF III, Davies WM, Brendel K (1985) Dynamic organ culture of precision liver slices for in vitro toxicology. Life Sci 36:1367–1375
Srivastava PK, Sharma VK, Kalonia DS, Grant DF (2004) Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure. Arch Biochem Biophys 427:164–169
Stadie WC, Riggs BC (1944) Microtome for the preparation of tissue slices for metabolic studies of surviving tissue in vitro. J Biol Chem 154:687–690
Stefaniak MS, Gandolfi AJ, Brendel K (1988) Adult rat lung in dynamic organ culture: a new tool in pharmacology. Proc West Pharmacol Soc 31:149–151
Strange RC, Spiteri MA, Ramachandran S, Fryer AA (2001) Glutathione-S-transferase family of enzymes. Mutat Res Fundam Mol Mech Mutagen 482:21–26
Stratford RE, Clay MP, Heinz BA, Kuhfeld MT, Osborne SJ, Philips DL, Swetana SA, Tebbe MJ, Vasudevan V, Zornes LZ, Lindstrom TD (1999) Application of oral bioavailability surrogates in the design of orally active inhibitors of rhinovirus replication. J Pharm Sci 88:747–753
Sumida K, Ooe N, Nagahori H, Saito K, Isobe N, Kaneko H, Nakatsuka I (2001) An in vitro reporter gene assay method incorporating metabolic activation with human and rat S9 or liver microsomes. Biochem Biophys Res Commun 280:85–91
Swift B, Pfeifer ND, Brouwer KLR (2010) Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev 42:446–471
Syme MR, Paxton JW, Keelan JA (2004) Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 43:487–514
Tabrett CA, Coughtrie MWH (2003) Phenol sulfotransferase 1A1 activity in human liver: kinetic properties, interindividual variation and re-evaluation of the suitability of 4-nitrophenol as a probe substrate. Biochem Pharmacol 66:2089–2097
Testa B, Jenner P (1976) Drug metabolism: chemical and biochemical aspects. Part II: biochemical aspects of drug oxidation. In: Swarbrick J (ed) Drug and the pharmaceutical science. Marcel Dekker Inc, New York, pp 271–312
Thomas NL, Coughtrie MWH (2003) Sulfation of apomorphine by human sulfotransferases: evidence of a major role for the polymorphic phenol sulfotransferase, SULT1A1. Xenobiotica 33:1139–1148
Thompson AM, Robertson RC, Bauer TA (1968) A rat head-perfusion technique developed for the study of brain uptake of materials. J Appl Physiol 24:407–411
Tucker GT, Houston JB, Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential – towards a consensus. Pharm Res 18:1071–1080
Tynes E, Hodgson E (1984) The measurement of FAD-containing monooxygenase activity in microsomes containing cytochrome P-450. Xenobiotica 14:515
Udata C, Tirucherai G, Mitra AK (1999) Synthesis, stereoselective enzymatic hydrolysis and skin permeation of diastereomeric propranolol ester prodrugs. J Pharm Sci 88:544–550
US-FDA (U.S. Food and Drug Administration) Guidance (2008) Guidance for industry. Safety testing of drug metabolites. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf. Accessed in Dec 2011
US-FDA (U.S. Food and Drug Administration) Guidance (2012) Guidance for industry. Drug interaction studies – study design, data analysis, implications for dosing and labeling recommendations. Draft guidance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed in July 2012
Vandenbranden M, Wrighton SA, Ekins S, Gillespie JS, Binkley SN, Ring BJ, Gadberry MG, Mullins DC, Strom SC, Jensen CB (1998) Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices. Drug Metab Dispos 26:1063–1068
Vere-Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL (1989) Selection of an oral prodrug (BRL 42810, famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine, penciclovir]. Antimicrob Agents Chemother 33:1765–1773
Vinci B, Duret C, Klieber S, Gerbal-Chaloin S, Sa-Cunha A, Laporte S, Suc B, Maurel P, Ahluwalia A, Daujat-Chavanieu M (2011) Modular bioreactor for primary human hepatocyte culture: medium flow stimulates expression and activity of detoxification genes. Biotechnol J 6:554–564
Von Bahr C, Groth CG, Jansson H, Lundgren G, Lind M, Glauman H (1980) Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin Pharmacol Ther 27:711
Walle T, Walle UK, Knapp DR, Conradi EC, Bargar EM (1983) Identification of major sulfate conjugates in the metabolism of propranolol in dog and man. Drug Metab Dispos 11:344–349
Wang J (2009) Comprehensive assessment of ADMET risks in drug discovery. Curr Pharm Des 15:2195–2219
Wang RW, Lu AY (1997) Inhibitory anti-peptide antibody against human CYP3A4. Drug Metab Dispos 25:762
Wang A, Xia T, Ran P, Chen X, Nuessler A-K (2002) Qualitative study of three cell culture methods. J Huazhong Univ Sci Technolog Med Sci 22:288–291
Watt AP, Mortishire-Smith RJ, Gerhard U, Thomas SR (2003) Metabolite identification in drug discovery. Curr Opin Drug Discov Devel 6:57
Weaver RJ, Jochemsen R (2009) Nonclinical pharmacokinetics and toxicokinetics. In: Cartwright AC, Mathews BC (eds) International pharmaceutical product registration. Informa Healthcare, London, New York, pp 336–376
Wei ZY, Brown W, Takaski B, Plobeck N, Delorme D, Zhou F, Yang H, Jones P, Gawell L, Ggnon H, Schmidt R, Yue SY, Walpole C, Payza K, St-Onge S, Labrre M, Godbout C, Jakob A, Butterworth J, Kamassah A, Morin PE, Projean D, Ducharme J, Robert E (2000) N, N-diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent & opioid receptor agonist with oral bioavailability and its analogues. J Med Chem 43:3895–3905
Weinshilboum RM, Otterness DM, Szumlanski CL (1999) Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 39:19–52
White RE (2001) High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol 40:133–157
Wienkers LC, Stevens JC (2003) Cytochrome P450 reaction phenotyping. In: Lee JS, Obach RS, Fisher MB (eds) Drug metabolizing enzymes, cytochrome P450 and other enzymes in drug discovery and development. Marcel Dekker, New York, pp 255–310
Williams FM (1987) Serum enzymes of drug metabolism. Pharmacol Ther 34:99–109
Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE (2004) Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCI/AUC) ratios. Drug Metab Dispos 32:1201–1208
Wittman MD, Altstadt TJ, Fairchild C, Hansel S, Johnston K, Kadow JF, Long BH, Rose WC, Vyas DM, Wu MJ, Zoeckler ME (2001) Synthesis of metabolically blocked paclitaxel analogues. Bioorg Med Chem Lett 11:809–810
Wittman MD, Kadow JK, Vyas DM (2000) Stereospecific synthesis of the major human metabolite of paclitaxel. Tetrahedron Lett 41:4729
Wójcikowskia J, Pichard-Garcia L, Maurel P, Daniel WA (2004) The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol 14:199–208
Wormhoudt LW, Commandeur JN, Vermeulen NP (1999) Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 29:59–124
Wrighton SA, Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1–21
Wynalda MA, Hutzler JM, Koets MD, Podoll T, Wienkers LC (2003) In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos 31:878–887
Xu ZH (2001) Human 3′-phosphoadenosine 5′-phosphosulfate synthetase: radiochemical enzymatic assay, biochemical properties, and hepatic variation. Drug Metab Dispos 29:172–178
Yagen B, Bergmann F, Barel S, Sintov A (1991) Metabolism of T-2 toxin by rat brain homogenate. Biochem Pharmacol 42:949–951
Yamazaki H, Inoue K, Turvy CG, Guengerich FP, Shimada T (1997) Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab Dispos 25:168–174
Yost GS (1999) Sites of metabolism: lung. In: Wolf TF (ed) Handbook of drug metabolism. Marcel Dekker, New York, pp 263–278
Yu H, Adedoyin A (2003) ADME-Tox in drug discovery: integration of experimental and computational technologies. Drug Discov Today 8:852–861
Zhang H, Davis CD, Sinz MW, Rodrigues AD (2007) Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667–687
Zhang J, Dean RA, Brzezinski MR, Bosron WF (1996) Gender-specific differences in activity and protein levels of cocaine carboxylesterase in rat tissue. Life Sci 59:1175–1184
Zhang JY, Wang Y, Prakash C (2006) Xenobiotic-metabolizing enzymes in the human lung. Curr Drug Metab 7:939–948
Zhang Z, Zhu M, Tang W (2009) Metabolite identification and profiling in drug design: current practice and future directions. Curr Pharm Des 15:2220–2235
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Dudda, A., Kuerzel, G.U. (2013). Metabolism Studies In Vitro and In Vivo. In: Vogel, H.G., Maas, J., Hock, F.J., Mayer, D. (eds) Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-25240-2_46
Download citation
DOI: https://doi.org/10.1007/978-3-642-25240-2_46
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-25239-6
Online ISBN: 978-3-642-25240-2
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences